Neurometrix (NURO)

Neurometrix (NURO) Stock Price & Analysis


NURO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.93 - $4.73
Previous Close$1.01
Average Volume (3M)52.78K
Market Cap
Enterprise Value-$11.69M
Total Cash (Recent Filing)$20.25M
Total Debt (Recent Filing)$328.74K
Price to Earnings (P/E)-1.5
Jul 20, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding7,839,549
10 Day Avg. Volume48,242
30 Day Avg. Volume52,777
Standard Deviation0.51
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)4.77
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.01
Enterprise Value/Gross Profit-2.03
Enterprise Value/Ebitda-6.77
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Neurometrix’s price range in the past 12 months?
Neurometrix lowest stock price was $0.93 and its highest was $4.73 in the past 12 months.
    What is Neurometrix’s market cap?
    Currently, no data Available
    When is Neurometrix’s upcoming earnings report date?
    Neurometrix’s upcoming earnings report date is Jul 20, 2023 which is in 48 days.
      How were Neurometrix’s earnings last quarter?
      Neurometrix released its earnings results on May 03, 2023. The company reported -$0.205 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.205.
        Is Neurometrix overvalued?
        According to Wall Street analysts Neurometrix’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Neurometrix pay dividends?
          Neurometrix does not currently pay dividends.
          What is Neurometrix’s EPS estimate?
          Neurometrix’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Neurometrix have?
          Neurometrix has 7,839,549 shares outstanding.
            What happened to Neurometrix’s price movement after its last earnings report?
            Neurometrix reported an EPS of -$0.205 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -23.741%.
              Which hedge fund is a major shareholder of Neurometrix?
              Currently, no hedge funds are holding shares in NURO


              Neurometrix Stock Smart Score

              This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
              Learn more about TipRanks Smart Score

              Company Description


              NeuroMetrix, Inc. is a healthcare company, which engages in the research, development, and trade of medical equipment and consumables. It offers an over-the-counter wearable therapeutic device for chronic pain, the Quell Health Cloud, DPNCheck, and pain management devices to treat chronic pain, nerve diseases, and sleep disorder. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.


              Top 5 ETFs holding NURO

              Market Value
              Smart Score
              iShares Core S&P Total U.S. Stock Market ETF
              Up to five ETFs with an Outperform Smart Score that hold NURO. The ETFs are listed according to market value of NURO within the ETF


              Forecast EPS vs Actual EPS

              Similar Stocks
              Price & Change
              Daré Bioscience
              Aethlon Medical
              Bio-Path Holdings

              Popular Stocks

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis